ArticleCanadian respiratory journal2026
Multiomics Approach Identifies Novel Genetic Determinants and Therapeutic Targets for Asthma.
Article in Canadian respiratory journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Multiomics Approach Identifies Novel Genetic Determinants and Therapeutic Targets for Asthma.Canadian respiratory journal · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Asthma constitutes a widespread chronic respiratory disease with multifactorial origins, in which definitive genetic components remain incompletely understood. This investigation synthesized transcriptomic data and Mendelian randomization (MR) to delineate causative genes contributing to asthma predisposition. Evaluation of the GSE43696 cohort disclosed 267 genes displaying expression alterations between healthy controls (n = 20) and asthmatic cases (n = 88). MR methods discerned seven causal genes, consisting of six protective determinants (GPRIN3, SHISA2, DUSP5, FCER1A, USP36, and LGALS2; OR < 1) and one risk-associated determinant (CXCL6; OR > 1). Independent validation with the GSE63142 series verified pronounced suppression of five genes in asthma specimens. Functional enrichment studies connected these genes to immune-related cascades, including IL-17/NF-κB signal transduction and Th17 cell differentiation, alongside metabolic activities. Single-cell transcriptomic assessment of 32,809 cells exposed compartmentalized expression profiles: FCER1A and LGALS2 predominated in dendritic cells, DUSP5 in goblet cells, SHISA2 in ionocytes, and USP36 in T cells. Immune cell infiltration evaluation demonstrated shifted distributions of mast cells, eosinophils, and monocytes, exhibiting substantial linkages with immune mediators such as CCR5 and CXCL10. Transcription factor exploration recognized cisbp__M0561 as the predominant regulatory element. Connectivity Map-based interrogation nominated KI-8751, verrucarin-A, and homoharringtonine as plausible therapeutic candidates. This consolidated multiomics framework elucidates previously uncharacterized pathological processes and prospective treatment avenues for asthma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.